# Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease

> **NCT04514510** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 46 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Isoquercetin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04514510
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-02
- **Primary completion:** 2022-06-13
- **Final completion:** 2022-07-07
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2024-01-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04514510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04514510, "Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04514510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*